IMPL Impel Pharmaceuticals Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Impel Pharmaceuticals Announces First Quarter 2022 Financial Results and Provides Corporate Update

   Trudhesa^® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021
   

   Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022

   Financing Agreement with Oaktree Capital Extends Cash Runway into 2024

   Impel to Host Investor Conference Call Today at 8:30 A.M. ET

   SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.

   "We are pleased to see continued strong growth…

   View Full Article
2. 12 May 2022 Impel Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference

   SEATTLE, May 12, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Adrian Adams, Chairman and Chief Executive Officer, will present a company overview at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022 at 5:00 p.m. ET in Miami, Florida.
   

   A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the presentation will be available on the website for 90 days.

   About Impel Pharmaceuticals …

   View Full Article
3. 09 May 2022 Impel Pharmaceuticals to Report First Quarter 2022 Financial Results on Monday, May 16, 2022

   SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, May 16, 2022, at 8:30 a.m. ET to report its first quarter 2022 financial results and provide a business update.
   

   The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 2468863. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay…

   View Full Article
4. 25 April 2022 Impel Neuropharma Announces Company Will Now Be Known as Impel Pharmaceuticals to Reflect Corporate Transformation

   SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is changing its name to Impel Pharmaceuticals. This new name reflects the ongoing corporate and strategic transformation of the Company and the use of its proprietary Precision Olfactory Delivery (POD^®) technology to treat patients suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system. The Company will celebrate this milestone, and its one-year anniversary as a publicly traded company, as Chairman of the Board and Chief Executive Officer…

   View Full Article
5. 21 April 2022 Impel NeuroPharma to Ring Nasdaq Closing Bell on Monday, April 25

   SEATTLE, April 21, 2022 (GLOBE NEWSWIRE) -- Impel NeuroPharma (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced that Chairman of the Board and Chief Executive Officer, Adrian Adams will ring the Nasdaq Stock Market closing bell on Monday, April 25, 2022. Impel is celebrating its one-year anniversary as a publicly traded company on the Nasdaq Stock Market.
   

   "We are honored to be ringing the Nasdaq closing bell today. In our first year as a public company, we received approval for, and successfully launched, our first product, Trudhesa® for the acute treatment…

   View Full Article